Search

Your search keyword '"Offidani A"' showing total 4,136 results

Search Constraints

Start Over You searched for: Author "Offidani A" Remove constraint Author: "Offidani A"
4,136 results on '"Offidani A"'

Search Results

151. Bortezomib-dexamethasone as maintenance therapy or early retreatment at biochemical relapse versus observation in relapsed/refractory multiple myeloma patients: a randomized phase II study

152. Clinical features and survival of multiple myeloma patients harboring t(14;16) in the era of novel agents

153. Prognostic or predictive value of circulating cytokines and angiogenic factors for initial treatment of multiple myeloma in the GIMEMA MM0305 randomized controlled trial

154. Achievement and maintenance of therapeutic response to brodalumab in patients with moderate‐to‐severe plaque psoriasis: An Italian, observational, retrospective and prospective study (BRIGHT study).

155. Novel Immunotherapies and Combinations: The Future Landscape of Multiple Myeloma Treatment.

157. Belantamab Mafodotin: From Clinical Trials Data to Real Life Experiences

159. Solar-driven valorization of glycerol towards production of chemicals and hydrogen

161. Treat-to-Target Approach for the Management of Patients with Moderate-to-Severe Plaque Psoriasis: Consensus Recommendations

162. Hidradenitis suppurativa and adalimumab in the COVID-19 era

163. Patient-centered practice in elderly myeloma patients: an overview and consensus from the European Myeloma Network (EMN)

164. Maintenance in myeloma patients achieving complete response after upfront therapy: a pooled analysis

165. Multidisciplinary Management of Spondyloarthritis-Related Immune-Mediated Inflammatory Disease

167. Carfilzomib and Lenalidomide for the Treatment of Primary Plasma Cell Leukemia: Final Results of the Prospective Phase 2 EMN12/HOVON-129 Study for Patients Aged ≥66 Years

168. Long Term Survival in Multiple Myeloma Patients: A Multicenter Italian Experience

169. Treatment of Primary Plasma Cell Leukemia with Carfilzomib and Lenalidomide-Based Therapy: Results of the Final Analysis of the Prospective Phase 2 EMN12/HOVON-129 Study for Patients Aged 18-65 Years

170. Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial

171. Supplementary Figure S2 from Development and Validation of a Simplified Score to Predict Early Relapse in Newly Diagnosed Multiple Myeloma in a Pooled Dataset of 2,190 Patients

172. TRIPOD Checklist from Development and Validation of a Simplified Score to Predict Early Relapse in Newly Diagnosed Multiple Myeloma in a Pooled Dataset of 2,190 Patients

173. Supplementary Figure 4 from Biological and Clinical Relevance of miRNA Expression Signatures in Primary Plasma Cell Leukemia

174. Supplementary Figure 4 from Transcriptional Characterization of a Prospective Series of Primary Plasma Cell Leukemia Revealed Signatures Associated with Tumor Progression and Poorer Outcome

175. Supplementary Figure 3 from Transcriptional Characterization of a Prospective Series of Primary Plasma Cell Leukemia Revealed Signatures Associated with Tumor Progression and Poorer Outcome

176. Supplementary Table 2 from Biological and Clinical Relevance of miRNA Expression Signatures in Primary Plasma Cell Leukemia

177. Supplementary Figure 2 from Transcriptional Characterization of a Prospective Series of Primary Plasma Cell Leukemia Revealed Signatures Associated with Tumor Progression and Poorer Outcome

178. Supplementary Figure 1 from Biological and Clinical Relevance of miRNA Expression Signatures in Primary Plasma Cell Leukemia

179. Supplementary Table 3 from Transcriptional Characterization of a Prospective Series of Primary Plasma Cell Leukemia Revealed Signatures Associated with Tumor Progression and Poorer Outcome

180. Supplementary Appendix from Development and Validation of a Simplified Score to Predict Early Relapse in Newly Diagnosed Multiple Myeloma in a Pooled Dataset of 2,190 Patients

181. Supplementary Table 1 from Biological and Clinical Relevance of miRNA Expression Signatures in Primary Plasma Cell Leukemia

183. Supplementary Table 2 from Transcriptional Characterization of a Prospective Series of Primary Plasma Cell Leukemia Revealed Signatures Associated with Tumor Progression and Poorer Outcome

184. Supplementary Table 1 from Transcriptional Characterization of a Prospective Series of Primary Plasma Cell Leukemia Revealed Signatures Associated with Tumor Progression and Poorer Outcome

185. Supplementary Methods from Biological and Clinical Relevance of miRNA Expression Signatures in Primary Plasma Cell Leukemia

186. Supplementary Figure 1 from Transcriptional Characterization of a Prospective Series of Primary Plasma Cell Leukemia Revealed Signatures Associated with Tumor Progression and Poorer Outcome

187. Supplementary Figure 5 from Biological and Clinical Relevance of miRNA Expression Signatures in Primary Plasma Cell Leukemia

188. Supplementary Figure 2 from Biological and Clinical Relevance of miRNA Expression Signatures in Primary Plasma Cell Leukemia

189. Supplementary Figure 3 from Biological and Clinical Relevance of miRNA Expression Signatures in Primary Plasma Cell Leukemia

194. The Impact of Treatment with IL-17/IL-23 Inhibitors on Subclinical Atherosclerosis in Patients with Plaque Psoriasis and/or Psoriatic Arthritis: A Systematic Review

195. Experts’ consensus on the definition and management of high risk multiple myeloma

198. Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM

199. Real-world evidence of biologic treatments in moderate-severe psoriasis in Italy: Results of the CANOVA (EffeCtiveness of biologic treAtmeNts for plaque psOriasis in Italy: An obserVAtional longitudinal study of real-life clinical practice) study

200. Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myeloma

Catalog

Books, media, physical & digital resources